Market Overview
Size, share, and clinical demand
- Brevintel analysis values the market at USD 2.9 billion in 2025 ($2.9B), rising to USD 6.2 billion by 2035 ($6.2B) at a 7.9% CAGR from 2026 to 2035.
- Industry estimates also place the industry near USD 3.1 billion in 2026 as preventive cardiac pathways and EHR-linked workflows expand.
- Baxter led with over 12% market share in 2025; Baxter, GE, Philips, Siemens Healthineers, and Nihon Kohden collectively held 27%.
- Demand is anchored in assessing cardiac electrical activity and functional response under exercise or pharmacological stress for ischemia, arrhythmia, and exercise intolerance.
- Cardiovascular disease affected 626 million people globally and caused 19.2 million deaths in 2023, accounting for 437 million disability-adjusted life years.
- The addressable testing population extends beyond confirmed coronary disease into risk stratification, pre-procedural evaluation, rehabilitation, and sports cardiology.
- In the United States, 130.6 million adults had some form of cardiovascular disease during 2021–2023, and CVD caused 915,973 deaths in 2023.
- Headline cards align with the narrative path: $2.9B base year, $6.2B forecast year, and 7.9% CAGR across 2026–2035.
Technology and workflow modernization
- Wireless acquisition modules reduce cable constraints during treadmill or ergometer testing, while HL7 and DICOM connectivity move results into enterprise cardiology and EHR systems.
- GE HealthCare CASE platforms illustrate integrated cardiac assessment with optional wireless ECG acquisition and exercise-testing workflows.
- AliveCor received FDA clearance and commercially launched its Kardia 12L system in June 2024, expanding portable acquisition options.
- Anumana received FDA 510(k) clearance in October 2023 for its ECG-AI low-ejection-fraction algorithm, validated in a 16,000-patient retrospective study with an AUROC of 0.932.
- AI-enabled ECG tools expand the analytical ecosystem around ECG data rather than replacing exercise-testing indications.
- Philips ECG AI Marketplace and Anumana algorithm access show how software can become part of the cardiac diagnostic platform proposition.
- Growth is uneven by care setting: large hospitals justify integrated platforms through service-line volume, while smaller sites favor modular and portable configurations.
- Brevintel analysis places commercial value with systems that make high-volume testing easier to acquire, interpret, archive, and distribute across care sites.
Market Dynamics
Key drivers
- Rising cardiovascular prevalence sustains demand for inducible ischemia, functional capacity, and exercise-related electrical assessment across hospital and outpatient pathways.
- Global CVD prevalence reached 626 million cases in 2023, while ischemic heart disease remained a leading contributor to cardiovascular disability burden.
- U.S. CVD affected 130.6 million adults in 2021–2023 and caused 915,973 deaths in 2023, supporting testing capacity across cardiology departments and follow-up pathways.
- The EU Council adopted cardiovascular health conclusions in December 2024; the ESC reports more than 5 million new CVD cases annually in the EU and nearly 53 million people living with the disease.
- 2024 ESC chronic coronary syndrome guidelines reinforce non-invasive stress testing for patients with appropriate pre-test probability of obstructive coronary disease.
- Italy has required pre-participation sports evaluation including resting ECG and exercise stress testing since 1982, with COCIS protocols updated during 2023–2024.
- Israel’s statutory athlete program includes ECG and Bruce-protocol exercise stress testing; Florida’s 2025 SB 1070 established ECG testing requirements for student athletes.
- EHR integration reduces paper workflows and repeat examinations; Philips ST80i supports HL7 and DICOM reporting with IntelliSpace ECG access, aligning devices to enterprise data architecture.
Key restraints
- Capital cost remains a constraint when purchases include acquisition hardware, treadmill or ergometer interfaces, blood-pressure modules, software, installation, training, calibration, and service.
- The United Kingdom’s 2026 NHS framework for cardiac and pulmonary diagnostics and exercise stress-testing solutions carried an estimated value of about GBP 92 million including VAT.
- Hospital purchasing studies show non-optimal procurement methods can raise the cost of comparable high-cost medical equipment by an average of 8.3%.
- Smaller facilities and resource-constrained markets may not justify comprehensive system purchases when utilization is uncertain.
- Buyers may retain older platforms longer when integration, accessories, and service contracts raise total cost of ownership.
- Portable and wireless configurations can reduce infrastructure needs but do not remove clinical oversight, quality assurance, and data-management requirements.
- Brevintel analysis notes that clinical need supports expansion, yet capital, trained personnel, reimbursement, and electronic workflow integration determine installed capacity.
- Wireless, portable, and AI-enabled platforms can lower deployment friction for outpatient facilities without assuming lower hardware cost alone resolves access barriers.
Segmentation Analysis
By product type
- Exercise testing systems generated USD 1,460.09 million in 2025 and are forecast to reach USD 3,182.06 million by 2035, the largest product category, at an 8.14% CAGR.
- Their lead reflects coordinating ECG acquisition, exercise protocols, physiological measurements, and reporting in a single clinical workflow under 2024 ESC guidance pathways.
- GE CASE supports optional wireless ECG acquisition; Schiller CS-300 combines wireless 12-lead acquisition, pharmacological stress capability, and EMR/PACS connectivity.
- Stress ECG accounted for USD 757.13 million in 2025 and is expected to reach USD 1,591.79 million by 2035 at a 7.75% CAGR.
- Segment growth is increasingly tied to software quality, interpretation support, and interoperability around serial electrical assessment during exertion.
- Stress blood pressure monitors represented USD 429.19 million in 2025 and are projected to reach USD 840.50 million by 2035, often purchased for platform compatibility.
- Pulse oximeters generated USD 273.71 million in 2025 and are expected to reach USD 587.10 million by 2035, supporting cardiopulmonary exercise and exertional desaturation assessment.
- AARC guidance treats a decline of at least 4% in SpO2 as clinically significant; Nonin’s 8000R forehead sensor targets stress testing under motion and low-perfusion conditions.
By end use
- Hospitals represented USD 1,354.34 million in 2025 and are forecast to reach USD 2,955.80 million by 2035 at an 8.16% CAGR, with a 46.4% revenue share in 2025.
- Hospital leadership reflects concentrated cardiology expertise, emergency and inpatient referral pathways, and the ability to justify integrated multi-user systems.
- Diagnostic centers generated USD 810.92 million in 2025 and are expected to reach USD 1,694.70 million by 2035, favoring throughput, rapid reporting, and EHR connectivity to external referrers.
- Ambulatory surgical centers accounted for USD 580.52 million in 2025 and are projected to reach USD 1,247.69 million by 2035, tied to outpatient cardiovascular and pre-procedural workflows.
- Other end users—specialty clinics, rehabilitation, research, and sports medicine—generated USD 174.34 million in 2025 and are expected to reach USD 303.26 million by 2035.
- Exercise testing systems grow faster than the total market because they sit where ECG, hemodynamic data, protocol management, and reporting must be coordinated.
- Hospitals monetize integration across a broad patient base; diagnostic centers and ambulatory settings need efficient turnover and simple result transmission.
- Brevintel analysis expects vendors that tailor connectivity, service, and acquisition hardware to these operating realities to compete more effectively than one-size high-acuity configurations.
Regional Outlook
North America and Europe
- North America generated USD 974.86 million in 2025 and is expected to reach USD 1,949.40 million by 2035 at a 7.21% CAGR, with a 33.4% regional share in 2025.
- The United States accounted for USD 922.60 million in 2025, while Canada accounted for USD 52.25 million.
- U.S. demand is supported by disease burden and reimbursement: CMS maintains local coverage determinations for outpatient cardiac stress testing (LCD L38396).
- Europe was valued at USD 753.88 million in 2025 and is projected to reach USD 1,566.62 million by 2035 at a 7.63% CAGR.
- Germany, the UK, France, Spain, Italy, and the Netherlands are central markets within the regional care ecosystem.
- ESC estimates nearly 53 million people live with CVD in the EU and that the disease cost Europe EUR 282 billion in 2021.
- The NHS exercise stress-testing framework (notice 012699-2026) aggregates demand while raising tender compliance, lifecycle cost, and interoperability requirements.
- North America converts disease burden through mature reimbursement; Europe rewards guideline-aligned, interoperable systems via formal procurement structures.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific is the fastest-growing region, rising from USD 761.35 million in 2025 to USD 1,746.69 million in 2035 at an 8.69% CAGR.
- China, Japan, India, Australia, and South Korea represent the core country scope.
- CVD affected 341.6 million people in Asia Pacific in 2021, equivalent to 55.8% of global prevalent cases, and caused 12.0 million deaths.
- India’s reported adult hypertension prevalence of approximately 35.5% signals the scale of risk factors feeding future cardiovascular assessment needs.
- Siemens Healthineers’ tele-cardiology partnership with iMedrix in Southeast Asia illustrates connected ECG workflows extending specialist interpretation beyond major urban centers.
- Latin America generated USD 309.29 million in 2025 and is projected to reach USD 679.94 million by 2035 at an 8.23% CAGR, led by Brazil, Mexico, and Argentina.
- Mexico’s IMSS announced MXN 1.7 billion for 123 high-technology diagnostic and imaging systems; cardio-renal-metabolic protocols become mandatory for public institutions effective August 25, 2026.
- Middle East and Africa was valued at USD 120.74 million in 2025 and is forecast to reach USD 258.80 million by 2035 at a 7.96% CAGR; Saudi Arabia targets about USD 66 billion in healthcare infrastructure investment during 2021–2030, with five new hospitals and 963 cardiovascular-ready beds planned by 2025, plus a Ministry of Health contract of SAR 67.2 million covering cardiac imaging archiving and rhythm-management infrastructure.
Competitive Landscape
Competitive structure and recent moves
- Baxter, Nihon Kohden, GE, Philips, and Siemens Healthineers collectively accounted for approximately 27% of the global market in 2025.
- Advantage increasingly depends on combining diagnostic performance with wireless acquisition, clinical software, interoperability, and hospital-to-outpatient service footprints.
- Baxter participates through its Q-Stress portfolio via the USD 10.5 billion Hillrom acquisition completed in December 2021; Hillrom had acquired Mortara in 2017.
- Q-Stress offers the VERITAS interpretation algorithm, wireless acquisition, and HL7/DICOM support around connectivity plus conventional stress-testing functionality.
- GE competes through CASE and CardioSoft; CASE V7.0 and CardioSoft V7.0 received FDA 510(k) clearance in December 2023, with a new CASE system introduced at ACC 2025 in March 2025.
- Philips differentiates via ST80i, IntelliSpace ECG, Cardiac Workstation launch in Europe, the Middle East, and Africa in June 2024, and ECG AI Marketplace launch in the United States in July 2025.
- Nihon Kohden offers cardiofax V ECG-2450 systems with stress-test software and DICOM connectivity, plus the STS-2100 exercise stress-testing platform.
- MGC Diagnostics received FDA 510(k) clearance for Ascent cardiorespiratory diagnostic software in October 2024; Halma’s April 2026 sale of Cardios to Cardioline reshaped Latin American ambulatory cardiac diagnostics ownership.
Integrated producers
- Baxter
- GE (General Electric)
- Philips
- Siemens Healthineers
- Nihon Kohden
Specialty suppliers
- Schiller
- COSMED
- MGC Diagnostics
- Nonin
- OSI Systems (Spacelabs)
- Fukuda
- Vyaire Medical